HRP20190706T1 - Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina - Google Patents

Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina Download PDF

Info

Publication number
HRP20190706T1
HRP20190706T1 HRP20190706TT HRP20190706T HRP20190706T1 HR P20190706 T1 HRP20190706 T1 HR P20190706T1 HR P20190706T T HRP20190706T T HR P20190706TT HR P20190706 T HRP20190706 T HR P20190706T HR P20190706 T1 HRP20190706 T1 HR P20190706T1
Authority
HR
Croatia
Prior art keywords
human
human immunoglobulin
heavy chain
mouse
sequence
Prior art date
Application number
HRP20190706TT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Babb
John Mcwhirter
Lynn Macdonald
Sean Stevens
Samuel Davis
David R. Buckler
Karolina A. Meagher
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/798,455 external-priority patent/US9796788B2/en
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HRP20190706T1 publication Critical patent/HRP20190706T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HRP20190706TT 2013-03-13 2014-03-13 Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina HRP20190706T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/798,455 US9796788B2 (en) 2010-02-08 2013-03-13 Mice expressing a limited immunoglobulin light chain repertoire
PCT/US2014/026040 WO2014160202A1 (en) 2013-03-13 2014-03-13 Mice expressing a limited immunoglobulin light chain repertoire
EP14717331.4A EP2967013B1 (en) 2013-03-13 2014-03-13 Mice expressing a limited immunoglobulin light chain repertoire

Publications (1)

Publication Number Publication Date
HRP20190706T1 true HRP20190706T1 (hr) 2019-10-18

Family

ID=50483561

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20190706TT HRP20190706T1 (hr) 2013-03-13 2014-03-13 Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina
HRP20230490TT HRP20230490T1 (hr) 2013-03-13 2014-03-13 Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20230490TT HRP20230490T1 (hr) 2013-03-13 2014-03-13 Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina

Country Status (26)

Country Link
EP (4) EP4545567A3 (OSRAM)
JP (4) JP6529957B2 (OSRAM)
KR (2) KR102295842B1 (OSRAM)
CN (2) CN108611369B (OSRAM)
AU (3) AU2014244020B2 (OSRAM)
BR (1) BR112015022034B1 (OSRAM)
CA (1) CA2903698C (OSRAM)
CY (1) CY1121545T1 (OSRAM)
DK (2) DK2967013T3 (OSRAM)
ES (3) ES3013063T3 (OSRAM)
FI (1) FI3501272T3 (OSRAM)
HR (2) HRP20190706T1 (OSRAM)
HU (2) HUE061977T2 (OSRAM)
IL (2) IL240563B (OSRAM)
LT (2) LT3501272T (OSRAM)
MX (3) MX391010B (OSRAM)
PL (2) PL2967013T3 (OSRAM)
PT (2) PT3501272T (OSRAM)
RS (2) RS58669B1 (OSRAM)
RU (1) RU2689664C2 (OSRAM)
SG (2) SG10201801101QA (OSRAM)
SI (2) SI2967013T1 (OSRAM)
SM (2) SMT201900196T1 (OSRAM)
TR (1) TR201901668T4 (OSRAM)
WO (1) WO2014160202A1 (OSRAM)
ZA (2) ZA201505835B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
US10246509B2 (en) 2011-10-17 2019-04-02 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
SMT201800435T1 (it) * 2013-02-20 2018-09-13 Regeneron Pharma Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
IL302725A (en) 2016-01-13 2023-07-01 Regeneron Pharma Rodents having an engineered heavy chain diversity region
CN111148758B (zh) * 2017-09-29 2022-12-09 瑞泽恩制药公司 结合葡萄球菌属靶抗原和补体成分的双特异性抗原结合分子及其用途
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
WO2020132557A1 (en) * 2018-12-21 2020-06-25 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
US11464217B2 (en) 2019-02-22 2022-10-11 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
IL298632A (en) 2020-06-02 2023-01-01 Biocytogen Pharmaceuticals Beijing Co Ltd Non-human animals genetically modified with a common light chain immunoglobulin locus
IL303868A (en) 2020-12-23 2023-08-01 Regeneron Pharma Nucleic acids encoding anchor-modified antibodies and uses thereof
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
CN114736927A (zh) * 2022-05-19 2022-07-12 东北大学 一种单抗克隆与表达载体的构建及应用
TW202430641A (zh) * 2023-01-18 2024-08-01 美商基利科學股份有限公司 人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
WO2007117410A2 (en) * 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
ITMI20071522A1 (it) * 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
ES2445193T3 (es) 2008-06-27 2014-02-28 Merus B.V. Mamíferos no humanos productores de anticuerpos
KR101711222B1 (ko) * 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
US20130045492A1 (en) * 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
MY195217A (en) * 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
IL315833A (en) * 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
RU2460287C1 (ru) * 2011-03-29 2012-09-10 Государственное образовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Трансгенная мышь, предназначенная для моделирования состояний, угрожающих развитием синдрома внезапной сердечной смерти при дистрофин-дефицитной кардиомиопатии
IL273982B2 (en) * 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals

Also Published As

Publication number Publication date
JP2016512034A (ja) 2016-04-25
BR112015022034A2 (pt) 2017-08-29
BR112015022034B1 (pt) 2023-02-28
FI3501272T3 (fi) 2023-04-06
IL240563B (en) 2021-03-25
IL240563A0 (en) 2015-09-24
ES3013063T3 (en) 2025-04-10
RS64185B1 (sr) 2023-05-31
CN108611369B (zh) 2022-08-26
ZA201505835B (en) 2019-09-25
PL3501272T3 (pl) 2023-07-03
KR20150126871A (ko) 2015-11-13
JP6529957B2 (ja) 2019-06-12
KR20210107911A (ko) 2021-09-01
MX391010B (es) 2025-03-21
EP4218409C0 (en) 2025-02-12
KR102424756B1 (ko) 2022-07-25
EP2967013A1 (en) 2016-01-20
DK2967013T3 (en) 2019-03-11
SI3501272T1 (sl) 2023-05-31
IL280892A (en) 2021-04-29
CA2903698C (en) 2023-02-28
LT3501272T (lt) 2023-03-27
EP3501272B1 (en) 2023-03-01
MX2020010837A (es) 2022-03-28
AU2020203238B2 (en) 2023-04-13
IL280892B2 (en) 2023-05-01
RS58669B1 (sr) 2019-06-28
WO2014160202A1 (en) 2014-10-02
IL280892B1 (en) 2023-01-01
JP6790136B2 (ja) 2020-11-25
AU2023202783A1 (en) 2023-05-25
NZ711776A (en) 2021-09-24
JP2019213549A (ja) 2019-12-19
EP2967013B1 (en) 2019-01-16
EP4218409B1 (en) 2025-02-12
CN105188357A (zh) 2015-12-23
PT2967013T (pt) 2019-04-03
ES2712207T3 (es) 2019-05-09
MX2015012539A (es) 2016-06-28
HK1218493A1 (en) 2017-02-24
HUE044003T2 (hu) 2019-09-30
EP4545567A3 (en) 2025-08-13
AU2014244020A1 (en) 2015-09-24
LT2967013T (lt) 2019-04-25
EP4218409A2 (en) 2023-08-02
AU2020203238A1 (en) 2020-06-11
TR201901668T4 (tr) 2019-02-21
MX377146B (es) 2025-03-07
EP3501272A1 (en) 2019-06-26
WO2014160202A4 (en) 2014-11-13
DK3501272T3 (da) 2023-04-03
PT3501272T (pt) 2023-03-29
RU2015143110A (ru) 2017-04-18
SG10201801101QA (en) 2018-04-27
ZA201805369B (en) 2021-08-25
PL2967013T3 (pl) 2019-07-31
CN105188357B (zh) 2018-04-24
EP4545567A2 (en) 2025-04-30
HUE061977T2 (hu) 2023-09-28
CY1121545T1 (el) 2020-05-29
SMT202300112T1 (it) 2023-05-12
RU2019115237A (ru) 2019-06-11
JP2020182490A (ja) 2020-11-12
SMT201900196T1 (it) 2019-05-10
CA2903698A1 (en) 2014-10-02
EP4218409A3 (en) 2023-08-30
JP2019076109A (ja) 2019-05-23
ES2942413T3 (es) 2023-06-01
DK3501272T5 (da) 2024-09-02
KR102295842B1 (ko) 2021-08-31
CN108611369A (zh) 2018-10-02
MX357308B (es) 2018-07-04
JP7010902B2 (ja) 2022-02-10
SI2967013T1 (sl) 2019-03-29
SG11201506278RA (en) 2015-09-29
HRP20230490T1 (hr) 2023-08-04
AU2014244020B2 (en) 2020-06-04
RU2689664C2 (ru) 2019-05-28

Similar Documents

Publication Publication Date Title
HRP20190706T1 (hr) Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina
RU2019121863A (ru) Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
HRP20161551T4 (hr) Miš sa zajedničkim lakim lancem
JP2015525071A5 (OSRAM)
RU2014153674A (ru) Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
JP2016512034A5 (OSRAM)
JP2015502177A5 (OSRAM)
HRP20211126T1 (hr) Humanizirane nehumane životinje s ograničenim lokusima imunoglobulinskog teškog lanca
HRP20190897T1 (hr) Laki lanac humaniziranih miševa
SI2840892T1 (en) Animals other than humans with modified immunoglobulin heavy chain sequences
RU2016141123A (ru) Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
JP2015519055A5 (OSRAM)
RU2017135754A (ru) Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
JP2014524243A5 (OSRAM)
HRP20191333T1 (hr) Glodavci koji izražavaju sekvence imunoglobulina osjetljive na ph vrijednost
JP2020530760A5 (OSRAM)
HRP20192218T1 (hr) Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
JP2014110814A5 (OSRAM)
HRP20170322T1 (hr) Miševi koji stvaraju vl vezne proteine
RU2021129958A (ru) Отличные от человека животные со сконструированным локусом легкой лямбда-цепи иммуноглобулина
HRP20190807T1 (hr) Miševi koji izražavaju imunoglobulinski hibridni laki lanac s humanom varijabilnom regijom
JP2010529042A5 (OSRAM)
JP2018138047A5 (OSRAM)
JP2019076109A5 (OSRAM)
JP2015505477A5 (OSRAM)